Atlas Venture Advisors, Inc. Larimar Therapeutics, Inc. Call Options Transaction History
Atlas Venture Advisors, Inc.
- $503 Million
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LRMR
# of Institutions
114Shares Held
60.9MCall Options Held
1.37MPut Options Held
124K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$198 Million3.33% of portfolio
-
Janus Henderson Group PLC London, X04.02MShares$37.5 Million0.02% of portfolio
-
Blue Owl Capital Holdings LP New York, NY3.99MShares$37.2 Million8.04% of portfolio
-
Goldman Sachs Group Inc New York, NY3.42MShares$31.9 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$31.8 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $403M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...